Table 4.

Atrial Premature Complexes and Ventricular Premature Complexes and Mortality in subgroup analysis

		All – Cause Mortality	CVD Mortality	IHD Mortality
		Hazard Ratio (95%CI)	Hazard Ratio (95%CI)	Hazard Ratio (95%CI)
Atrial Premature Complexes	Male	1.47(0.98–2.11)	1.52(0.83–2.52)	1.83(0.83–3.46)
	Female	1.53(1.12–2.04)	2.00(1.29–2.96)	2.79(1.68–4.34)
	Age ≥ 65 years	1.57(1.20–2.01)	1.70(1.17–2.46)	2.05(1.30–3.22)
	Age < 65 years	2.05(0.12–9.10)	1.43(1.06–1.95)	1.45(1.10–1.92)
	White	1.36 (0.98 – 1.85)	1.57(0.96 – 2.41)	2.03 (1.14 –3.34)
	Non-White	1.54 (0.96 – 2.32)	1.90 (0.94–3.41)	2.23 (0.87 – 4.69)
Ventricular Premature Complexes	Male	1.30(0.80–1.96)	1.14(0.52–2.13)	0.56 (0.09 – 1.75)
	Female	1.05(0.79–1.38)	1.21(0.78–1.78)	1.25(0.69–2.07)
	Age ≥ 65 years	1.36 (1.04–1.76)	0.83(0.53–1.30)	0.79(0.43–1.46)
	Age < 65 years	0.48(0.03–2.13)	0.75(0.56–1.01)	0.75(0.57–1.00)
	White	1.00(0.72–1.35)	0.87 (0.51–1.39)	0.85(0.40–1.57)
	Non-White	1.07(0.64–1.67)	1.01 (0.42–2.01)	0.83 (0.20–2.23)

CVD, cardiovascular disease; IHD, ischemic heart disease; Models adjusted for age, sex and race/ethnicity, smoking status, systolic blood pressure, body mass index, blood pressure medications, total cholesterol, diabetes mellitus, cancer and pulmonary disease (bronchial asthma and chronic obstructive pulmonary disease), electrocardiographic left ventricular hypertrophy, and corrected QT interval; No significant interactions observed between the components of each subgroups and the outcome